These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11580291)

  • 1. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
    Ploug M; Østergaard S; Gårdsvoll H; Kovalski K; Holst-Hansen C; Holm A; Ossowski L; Danø K
    Biochemistry; 2001 Oct; 40(40):12157-68. PubMed ID: 11580291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
    Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
    Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
    Ploug M
    Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
    Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
    Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking.
    Gårdsvoll H; Gilquin B; Le Du MH; Ménèz A; Jørgensen TJ; Ploug M
    J Biol Chem; 2006 Jul; 281(28):19260-72. PubMed ID: 16672229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
    Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
    Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
    Gårdsvoll H; Ploug M
    J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
    Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
    FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
    Ploug M
    Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis.
    Gårdsvoll H; Danø K; Ploug M
    J Biol Chem; 1999 Dec; 274(53):37995-8003. PubMed ID: 10608868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
    Engelholm LH; Behrendt N
    Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
    Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
    Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
    Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site.
    Muehlenweg B; Assfalg-Machleidt I; Parrado SG; Bürgle M; Creutzburg S; Schmitt M; Auerswald EA; Machleidt W; Magdolen V
    J Biol Chem; 2000 Oct; 275(43):33562-6. PubMed ID: 10913110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator.
    Kindzelskii AL; Amhad I; Keller D; Zhou MJ; Haugland RP; Garni-Wagner BA; Gyetko MR; Todd RF; Petty HR
    Histochem Cell Biol; 2004 Apr; 121(4):299-310. PubMed ID: 15042374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urokinase receptor as a potential target in cancer therapy.
    Romer J; Nielsen BS; Ploug M
    Curr Pharm Des; 2004; 10(19):2359-76. PubMed ID: 15279614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
    Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.